ClinicalTrials.gg
CompletedNCT06019494Updated Feb 7, 2024

Comparison of 2 Different Flow Rates During Oocyte Retrieval

An interventional study of Oocyte retrieval with low aspiration flow rate and Oocyte retrieval with high aspiration flow rate in Infertility, sponsored by Eugonia. Completed at 1 site in Greece. Open to female participants aged 18 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Eugonia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Infertility by Eugonia — none open to participants now, none under way, none of them phase 3. Infertility · Eugonia.

Enrollment
10th of 10
42 · median 84
Started
2023
the only one that year
No phase
5 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Infertility by Eugonia, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 5 with no phase, and was the 13th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 13 studies in Infertility by Eugonia is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 43 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Infertility by Eugonia as a file.
02

Study summary

The purpose of this study is to evaluate the effect of different flow rates during oocyte retrieval, on the number of cumulus oocyte complexes (COCs) retrieved.

Read the detailed description

In the current study, each ovary will be randomly allocated to oocyte retrieval using 0.42 ml/sec or 0.62 ml/sec flow rate.

The primary endpoint will be the number of oocytes retrieved, while secondary outcomes will include oocyte recovery rate (number of oocytes retrieved per follicle aspirated), number of mature oocytes, maturation rate (number of mature oocytes/number of oocytes retrieved), mean oocyte score (by evaluating oocyte shape and size, ooplasm characteristics, structure of perivitelline space (PVS), structure of zona pellucida (ZP) and polar body (PB) morphology), fertilization rate (number of fertilized oocytes/number of mature oocytes), number of blastocysts and blastulation rate (number of blastocysts/number of 2PN).

Patients aged 18-43 years with the presence of at least 3 follicles ≥ 11mm in each ovary on the day of oocyte retrieval will be eligible for inclusion in the study.

Prior to oocyte retrieval in eligible patients their left and right ovary will be randomly allocated into the 0.42 ml/sec or 0.62 ml/sec flow rate group. Randomisation with minimisation will be employed.

The specific flow rates will be achieved by adjusting the aspiration pressure of the vacuum pump accordingly. A study nurse will be responsible for adjusting the aspiration pressure of the vacuum pump depending on randomization. The doctor performing the oocyte retrieval will not be aware of the flow rate used in each ovary.

All follicles will be aspirated and then flushed if needed up to a maximum of 5 times with an open flushing technique, using a 16G double-lumen needle.

Data will be registered regarding the number of flushes required to retrieve a COC, the morphology of oocytes after denudation, oocyte fertilisation and embryo development up to the blastocyst stage.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Flow rate
  • Aspiration pressure
  • Oocyte retrieval
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of both ovaries
  • 18-43 years old
  • At least 3 follicles ≥ 11mm in each ovary on the day of oocyte retrieval

Exclusion criteria

Exclusion Criteria:

  • One or no ovaries present
  • Monofollicular development
  • Poor responders
  • Previous history of hemorrhage during oocyte retrieval
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Low aspiration flow rate

    All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.42ml/sec.

    Procedure: Oocyte retrieval with low aspiration flow rate

  • Experimental
    High aspiration flow rate

    All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.62ml/sec.

    Procedure: Oocyte retrieval with high aspiration flow rate

Interventions

  • ProcedureOocyte retrieval with low aspiration flow rate

    All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.

  • ProcedureOocyte retrieval with high aspiration flow rate

    High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved

    Number of oocytes retrieved per ovary randomised.

    Time frame: During oocyte retrieval

Secondary outcomes

  1. Oocyte recovery rate

    Number of oocytes retrieved per follicle aspirated.

    Time frame: During oocyte retrieval

  2. Oocyte maturation rate

    Number of mature (metaphase-II) oocytes divided by the number of oocytes retrieved per ovary randomised.

    Time frame: 2-3 hours post oocyte retrieval

  3. Average oocyte score

    Average oocyte score based on the evaluation of oocyte shape and size, ooplasm characteristics, structure of perivitelline space, structure of zona pellucida and polar body morphology.

    Time frame: 2-3 hours post oocyte retrieval

  4. Fertilization rate

    Number of fertilised (2PN) oocytes divided by the number of matured oocytes retrieved per ovary randomised.

    Time frame: Day 1 post oocyte retrieval

  5. Percentage of good quality blastocysts on day 5

    Number of good quality blastocysts divided by the number of fertilized oocytes per ovary randomised.

    Time frame: 5 days post oocyte retrieval

07

Study locations

1 site
  • Eugonia Unit of Assisted Reproduction
    Athens, 11528, Greece
08

References and documents

Publications

  • Lazzaroni-Tealdi E, Barad DH, Albertini DF, Yu Y, Kushnir VA, Russell H, Wu YG, Gleicher N. Oocyte Scoring Enhances Embryo-Scoring in Predicting Pregnancy Chances with IVF Where It Counts Most. PLoS One. 2015 Dec 2;10(12):e0143632. doi: 10.1371/journal.pone.0143632. eCollection 2015. PubMed 26630267 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jan 2024, 4 months.

Of 386 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 4 months is below that.

Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 31, 2023
StartActual
Sep 1, 2023
Primary completionActual
Jan 30, 2024
CompletionActual
Jan 31, 2024
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06019494
Lead sponsor
Eugonia
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Sep 1, 2023
Primary completion
Jan 30, 2024
Completion
Jan 31, 2024
Last update
Feb 7, 2024

Study contacts

George T Lainas, PhD
principal investigator · Eugonia ART Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion